Preeclampsia, a major cause of maternal and perinatal mortality and morbidity, is thought to be attributed, in part, to impaired trophoblast invasion. Peroxisome proliferator-activated receptors are ligand-activated transcription factors expressed in trophoblasts, which regulate the expression of a number of genes involved in cell differentiation and proliferation. We investigated the effect of...

OBJECTIVE Peripheral arterial disease is highly prevalent in the elderly and in the subjects with cardiovascular risk factors such as diabetes. Approximately 2% to 4% of those affected with peripheral arterial disease commonly complain of intermittent claudication. Cilostazol, a type III phosphodiesterase inhibitor, is the only Food and Drug Administration-approved drug for the treatment of int...

OBJECTIVE We tested the hypothesis that endothelial peroxisome proliferator-activated receptor-γ protects against vascular thrombosis using a transgenic mouse model expressing a peroxisome proliferator-activated receptor-γ mutant (E-V290M) selectively in endothelium. APPROACH AND RESULTS The time to occlusive thrombosis of the carotid artery was significantly shortened in E-V290M mice compare...

We recently isolated a novel co-activator of peroxisome proliferator-activated receptor γ, helicase with zinc finger 2 (HELZ2). HELZ2 null mice were resistant to diet-induced obesity and NAFFL/NASH, was phosphorylated at tyrosine residues. In order find factor related HELZ2, we analyzed products co-immunoprecipitated by mass spectrometry analyses. identified proline- glutamine-rich (SFPQ) as pr...

discussions in comparison to the control of wy14643, sandoz58-035, c9 and t11-cla, epa increased the pparα mrna levels (p = 0.024, p = 0.041, p = 0.043, and p = 0.004, respectively), even though, la had no significant effect on the pparα mrna expression (p = 0.489). materials and methods this experimental study investigated the effects of c9, t11-conjugated linoleic acid (c9, t11-cla). alpha li...